Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine,
Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation (weekly x 4)
, then one dose of rituximab every 12 weeks until 5 years or disease progression.